Women With Peripheral Arterial Disease Experience Faster Functional Decline Than Men With Peripheral Arterial Disease

Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
Journal of the American College of Cardiology (Impact Factor: 15.34). 02/2011; 57(6):707-14. DOI: 10.1016/j.jacc.2010.09.042
Source: PubMed

ABSTRACT We hypothesized that women with lower extremity peripheral arterial disease (PAD) would have greater mobility loss and faster functional decline than men with PAD.
Whether rates of mobility loss or functional decline differ between men and women with PAD is currently unknown.
Three hundred eighty men and women with PAD completed the 6-min walk, were assessed for mobility disability, and underwent measures of 4-m walking velocity at baseline and annually for up to 4 years. Computed tomography-assessed calf muscle characteristics were measured biannually. Outcomes included becoming unable to walk for 6 min continuously among participants who walked continuously for 6 min at baseline. Mobility loss was defined as becoming unable to walk for a quarter mile or to walk up and down 1 flight of stairs without assistance among those without baseline mobility disability. Results were adjusted for age, race, body mass index, physical activity, the ankle brachial index, comorbidities, and other confounders.
At 4 years of follow-up, women were more likely to become unable to walk for 6 min continuously (hazard ratio: 2.30, 95% confidence interval: 1.30 to 4.06, p = 0.004), more likely to develop mobility disability (hazard ratio: 1.79, 95% confidence interval: 1.30 to 3.03, p = 0.030), and had faster declines in walking velocity (p = 0.022) and the distance achieved in the 6-min walk (p = 0.041) compared with men. Sex differences in functional decline were attenuated after additional adjustment for baseline sex differences in calf muscle area.
Women with PAD have faster functional decline and greater mobility loss than men with PAD. These sex differences may be attributable to smaller baseline calf muscle area among women with PAD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Women are disproportionately affected by cardiovascular disease, often experiencing poorer outcomes following a cardiovascular event. Evidence points to inequities in processes of care as a potential contributing factor. This study sought to determine whether any sex differences exist in adherence to process of care guidelines for cardiovascular disease within primary care practices in Ontario, Canada.
    BMC Family Practice 06/2014; 15(1):123. DOI:10.1186/1471-2296-15-123 · 1.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives We sought to examine gender-related differences in outcomes related to PVI procedures. Background Percutaneous peripheral vascular intervention (PVI) is frequently performed for the treatment of peripheral arterial disease (PAD). However, little is known about gender-related differences related to PVI procedures. Methods We assessed the impact of gender among 12,379 patients (41% female) who underwent lower extremity (LE)-PVI from 2004 to 2009 at 16 hospitals participating in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium PVI registry. Multivariate propensity matched analyses were performed to adjust for differences in baseline characteristics, procedural indications and comorbidities based on gender. Results Compared with males, females were older, have multilevel disease and critical limb ischemia. In a propensity-matched analysis, female sex was associated with a higher rate of vascular complications, transfusions, and embolism. No differences were observed for in-hospital death, myocardial infarction or stroke/transient ischemic attack. Technical success was more commonly achieved in females (91.2% vs. 89.1%, p=0.014) but due to a higher complication rate, the overall procedural success rates were similar in men and women (79.7% vs. 81.6%, p=0.08). Conclusions Females represent a significant proportion of patients undergoing LE-PVI, have more severe and complex disease process, and are at increased risk for adverse outcomes. Despite higher complications rates, females had similar procedural success compared with men, making PVI an effective treatment strategy among women LE-PAD.
    Journal of the American College of Cardiology 06/2014; 63(23). DOI:10.1016/j.jacc.2014.03.036 · 15.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Women have high rates of peripheral artery disease (PAD) despite fewer cardiovascular disease (CVD) risk factors, compared to men. We sought to determine the gender-specific prevalence of low ankle brachial index (ABI) and the relationship to C-reactive protein (CRP) levels and CVD risk factors in the Life Line Screening population. Between April 2005 and August 2011, 133 750 women and 71 996 men had ABI and CRP measured at a Life Line Screening Center. Women were slightly older than men, whereas men were more likely to be current smokers, have diabetes mellitus (DM), and coronary artery disease (CAD) (P<0.001 for each). Women were more likely to have ABI≤1.0, compared to men (26.6% versus 14.4%, respectively; P<0.001), as well as ABI≤0.9 (4.1% women versus 2.6% men; P<0.001). Women had higher median CRP levels (1.94 mg/L; interquartile range [IQR], 0.89, 4.44 mg/L), compared to men (1.35 mg/L; IQR, 0.73, 2.80 mg/L; P<0.001). Men and women shared similar risk factors for ABI≤0.9, including older age, black race, smoking, DM, hypertension, hypercholesterolemia, CAD, and elevated CRP levels. In an adjusted model, there were significant interactions between gender and age (P<0.001), CRP (P<0.001), CAD (P=0.03), and DM (P=0.06) with ABI as the outcome. The associations between age, CRP, CAD, and DM with ABI≤0.9 were stronger in men than in women. Women participating in the Life Line Screening had higher CRP levels and a higher prevalence of PAD, compared to men. Neither higher CRP levels nor conventional CVD risk factors explained the excess prevalence of PAD in women.
    Journal of the American Heart Association 03/2014; 3(2):e000651. DOI:10.1161/JAHA.113.000651 · 2.88 Impact Factor


Available from